1mg + PharmEasy + NetMeds: TCS Section 52 Marketplace Reconciliation

A Tier-1 integrated pharma formulator’s direct-to-consumer team closes the Q2 FY 2026-27 quarter on the three principal Indian e-pharmacy marketplaces — 1mg (Tata 1mg subsidiary), PharmEasy (API Holdings) and NetMeds (Reliance Retail). Gross D2C sales on each platform for the quarter sit at the order of Rs 45 crore. Returns and chargebacks — expired-stock rejections, damaged-shipment returns, wrong-SKU returns, prescription-verification-failure returns — run at approximately 7 percent of gross, taking net supply value to Rs 41.8 crore per platform. Section 52 of the Central Goods and Services Tax Act 2017 requires each of the three marketplaces, in its capacity as an electronic commerce operator (ECO), to collect tax at source at the notified rate on that net supply value: 0.5 percent CGST plus 0.5 percent SGST for intra-state consumer purchases, or 1 percent IGST for inter-state purchases, aggregating to a 1 percent TCS of Rs 41.8 lakh per platform per quarter. Each marketplace files Form GSTR-8 by the tenth day of the month succeeding the calendar month of collection, and the TCS credit appears in the pharma supplier’s own GSTR-2A / GSTR-2B for utilisation against output tax liability in GSTR-3B. This is GST TCS marketplace pharma 1mg PharmEasy NetMeds Section 52 reconciliation at operating scale — and the discipline that separates a defensible weekly settlement close from a monthly variance investigation cycle is a per-platform per-week reconciliation workbook that ties the ECO’s settlement report at ORDER-ID granularity to the supplier’s own outward-supply register, holds the Section 34 credit-note register for reverse logistics as a distinct cost centre, and tracks the two-month working-capital lag between TCS deduction at the point of settlement and credit availability in the electronic cash ledger.

Quick reference

The reconciliation in one paragraph

A pharma D2C brand selling on any of 1mg, PharmEasy or NetMeds routes every consumer purchase through the marketplace’s payment aggregator wallet. The marketplace collects the full consumer consideration, holds the amount for a weekly or bi-weekly settlement cycle, and then remits the residual to the pharma supplier after deducting platform commission (typically 4 to 8 percent of gross depending on the SKU category — over-the-counter versus prescription, chronic-care versus acute-care), logistics recovery per the platform tariff, payment gateway charges of the order of 1.8 percent of gross collected, and Section 52 TCS on the net value of taxable supplies. The net value is computed at the aggregate month level per Section 52(1) of the CGST Act 2017 — gross taxable supplies through the operator reduced by taxable supplies returned to the supplier during the same month. The TCS rate is 0.5 percent CGST plus 0.5 percent SGST for intra-state sales (aggregating to 1 percent) or 1 percent IGST for inter-state sales. The marketplace files Form GSTR-8 monthly by the tenth of the succeeding month under Rule 67 of the CGST Rules 2017, and the TCS credit appears in the supplier’s GSTR-2A / GSTR-2B for utilisation in GSTR-3B. The reconciliation surface is platform-wise plus week-wise, with a two-month working-capital lag between TCS deduction at the point of weekly settlement and credit availability in the electronic cash ledger. The Section 34 credit-note register for expired-stock, damaged-shipment, wrong-SKU and prescription-verification-failure returns runs as a parallel reconciliation surface against the reverse-logistics tracker.

What the scenario looks like in India — the three-platform e-pharmacy channel

The Indian e-pharmacy channel is anchored by three principal marketplaces: 1mg (acquired by Tata Digital in 2021 and now operating as the Tata 1mg subsidiary), PharmEasy (operated by API Holdings, the parent that also owns the Thyrocare diagnostics business), and NetMeds (a wholly-owned subsidiary of Reliance Retail Ventures). All three operate the electronic commerce operator model under Section 2(45) of the CGST Act 2017 — they own, operate or manage a digital or electronic facility for the supply of goods, they collect the consumer consideration on behalf of the pharma supplier, and they attract Section 52 TCS liability on the net value of taxable supplies made through them. Apollo Pharmacy Online, Wellness Forever and MedPlus Online operate a smaller share of the same channel with the same tax mechanic. Amazon Pharmacy India is a subsequent entrant that has not yet reached the scale of the three principals.

Illustrative Tier-1 and Tier-2 pharma brands with a direct-to-consumer channel on the three marketplaces — dispatched either from the brand’s own fulfilment centre or from the marketplace’s bonded warehouse under an integrated fulfilment arrangement — include Cipla, Sun Pharmaceutical Industries, Dr Reddy’s Laboratories, Lupin, Zydus Lifesciences, Torrent Pharmaceuticals, Alkem Laboratories and Glenmark Pharmaceuticals across the Tier-1 integrated formulators, and Ajanta Pharma, JB Chemicals, Ipca Laboratories and Wockhardt across the Tier-2 speciality formulators. Consumer therapy areas driving the volume include chronic-care refills (anti-diabetic, anti-hypertensive, anti-lipid, thyroid), acute-care over-the-counter (analgesic, anti-cold, anti-allergy), and specialty categories where the marketplace channel has grown share (dermatology, women’s health, sexual wellness). The reconciliation this article walks through is generic to any Tier-1 or Tier-2 brand running a multi-platform D2C channel and generalises to the smaller marketplaces as well.

For the reconciliation this article walks through, the reference persona is a Tier-1 integrated pharma formulator’s D2C channel operating on all three of 1mg, PharmEasy and NetMeds at an illustrative Q2 FY 2026-27 gross of the order of Rs 45 crore per platform (aggregating Rs 135 crore across the three platforms for the quarter). The channel is a distinct cost centre within the pharma company’s overall FY 2026-27 domestic Chapter 30 turnover — separate GSTIN treatment applies at the state-fulfilment-centre level under the standard multi-state pharma manufacturing footprint documented in the Rule 89(5) inverted duty refund pharma formulations playbook. The D2C channel typically ships from a limited number of central fulfilment states (Maharashtra, Karnataka, Haryana, Tamil Nadu) into the pan-India consumer catchment, so the intra-state versus inter-state split of TCS liability is skewed toward IGST rather than CGST+SGST.

The regulatory overlay — Section 52, Notification 52/2018, Rule 67 and Section 34

Four anchors govern the pharma D2C marketplace reconciliation cycle. All four are procedural — the Section 52 TCS mechanic itself, the rate notification, the GSTR-8 filing rule, and the credit-note provision that governs the reverse-logistics leg.

Section 52 of the Central Goods and Services Tax Act 2017 requires every electronic commerce operator, not being an agent, to collect an amount calculated at the notified rate on the net value of taxable supplies made through it by other suppliers where the consideration for such supplies is to be collected by the operator. Sub-section (1) fixes the base as the net value — the aggregate value of taxable supplies of goods or services made during any month by all registered suppliers through the operator reduced by the aggregate value of taxable supplies returned to the suppliers during the said month. The Explanation to sub-section (1) makes it explicit that only taxable supplies count; nil-rated, exempt or non-GST supplies do not enter the base. The netting is at the aggregate month level per supplier, not at the invoice level — a return processed and refunded in a later month gets netted in that later month, not in the month of the original supply.

Notification 52/2018-Central Tax dated 20 September 2018 (issued alongside the corresponding State GST notifications and the parallel Notification 02/2018-Integrated Tax) fixes the rate at 0.5 percent under the CGST Act, 0.5 percent under the SGST Act, and 1 percent under the IGST Act. The effective TCS on any e-commerce sale is therefore 1 percent — split as CGST+SGST for intra-state supply through the operator and applied as IGST for inter-state supply. The 1 percent rate has not been revised since the September 2018 notification and remained in force through the 22 September 2025 rate reset that moved Chapter 30 formulations to 5 percent output GST (documented in the GST Council 56th meeting pharma 5 percent transition walkthrough) — the marketplace TCS rate is decoupled from the underlying output GST rate and continues at 1 percent regardless.

Rule 67 of the CGST Rules 2017 governs the ECO’s monthly filing discipline. The operator files Form GSTR-8 electronically on the GST common portal by the tenth day of the calendar month following the month of collection. Form GSTR-8 details, at the supplier-registration level, the aggregate value of supplies made through the operator, the aggregate value of returns netted, the net taxable supplies base, and the tax collected at source. The details are made available electronically to each supplier on the common portal after the filing due date. The TCS credit is credited to the supplier’s electronic cash ledger, appearing in the supplier’s own GSTR-2A auto-populated inward supplies statement and the GSTR-2B monthly cutover statement. The supplier utilises the credit in the GSTR-3B for the settlement month — filed by the 20th of the following month.

Section 34 of the CGST Act 2017 governs the credit-note treatment for the reverse-logistics leg of the marketplace channel. Where goods supplied are returned by the recipient, or the taxable value or tax charged in the original invoice exceeded the correct value, or the goods or services supplied are found to be deficient, the supplier issues a credit note to reduce the output tax liability. Section 34(2) requires the credit note to be declared in the supplier’s return for the month during which it was issued but not later than 30 November following the end of the financial year in which the original supply was made, or the date of furnishing the relevant annual return, whichever is earlier. For an expired-stock return on the marketplace channel the reconciliation window is tight — the pharma supplier must issue the Section 34 credit note within the calendar month of the physical return to preserve the output tax liability adjustment and the netting in the marketplace’s subsequent GSTR-8 filing.

A worked example — Cipla-style D2C channel on 1mg for Q2 FY 2026-27

Illustrative — the following figures represent the operating pattern of a Tier-1 pharma direct-to-consumer channel on the 1mg marketplace at a quarterly gross scale that Indian large-cap listed formulators typically operate. Public disclosures do not reveal per-platform per-quarter TCS-and-settlement reconciliation in the granularity below; cross-verify against your own platform settlement reports and GSTR-8 reflections before action.

The reference persona is a Tier-1 integrated pharma formulator’s D2C channel — Cipla in the illustrative — operating on 1mg for Q2 FY 2026-27. Quarterly gross D2C sales on the platform sit at Rs 45 crore. Returns and chargebacks — expired-stock rejections at approximately 3.5 percent of gross, damaged-shipment returns at approximately 1.5 percent, wrong-SKU returns at approximately 1.2 percent, prescription-verification-failure returns at approximately 0.8 percent — aggregate to approximately 7 percent of gross, or Rs 3.2 crore for the quarter. Net supply value on which Section 52 TCS applies is Rs 45.0 − Rs 3.2 = Rs 41.8 crore.

Applied at the platform level for the quarter, the aggregate deductions are: platform commission Rs 2.5 crore, logistics Rs 1.2 crore, payment gateway Rs 0.81 crore, Section 52 TCS Rs 41.8 lakh — totalling Rs 4.93 crore in platform-side deductions plus the Section 52 TCS separately. The Cipla D2C channel net receipt on 1mg for the quarter is of the order of Rs 36.9 crore against a gross of Rs 45 crore. Repeat the same reconciliation on PharmEasy and NetMeds at similar scale and the aggregate quarterly D2C net receipt across all three platforms is of the order of Rs 110 crore against a gross of Rs 135 crore.

The Section 52 TCS credit of Rs 41.8 lakh flows to Cipla’s electronic cash ledger via 1mg’s Form GSTR-8 filing by the 10th of each succeeding month. The credit appears in Cipla’s GSTR-2A auto-populated inward supplies statement and the GSTR-2B monthly cutover statement for the month M+1, and is utilised in Cipla’s own GSTR-3B for the settlement month M filed by 20th of M+1. The two-month working-capital lag between TCS deduction at the weekly settlement point and credit utilisation is approximately Rs 41.8 lakh per platform per quarter, or approximately Rs 1.25 crore of TCS-credit-in-transit across the three-platform channel at any given point in the year.

The Section 34 credit-note register for the quarter carries the Rs 3.2 crore aggregate return value. Each credit note is issued in the calendar month of the physical return to preserve the output tax liability adjustment and to feed the netting into 1mg’s subsequent-month GSTR-8 base. The expired-stock component (approximately Rs 1.6 crore) sits as a distinct cost centre against the therapy-area expired-stock provision — chronic-care refills carry a lower expired-stock rate than acute-care over-the-counter because the consumer purchase-to-consumption cycle is faster.

Common reconciliation breakages

Five breakages recur across pharma D2C channels running the multi-platform marketplace settlement cycle, and each maps to a specific control failure at the platform-supplier interface.

• TCS applied to gross rather than net-of-returns. The most common cause of a marketplace TCS variance is the platform applying Section 52 TCS to the gross settlement value for the week rather than the net-of-returns base for the calendar month. Section 52(1) unambiguously fixes the base as the net value at the month level — the aggregate value of taxable supplies of goods or services made during any month by all registered suppliers through the operator reduced by the aggregate value of taxable supplies returned to the suppliers during the said month. A platform that applies TCS on the weekly gross and does not net the following week’s returns creates an over-TCS position that only reconciles at the month-close TCS review — leaving the pharma supplier with a working-capital hit on the intervening weeks. Reconciliation discipline: the weekly settlement workbook holds both the platform-applied TCS (as reported by the platform) and the base-case TCS (Section 52-net-of-returns) as parallel lines, and the month-close reconciliation surfaces the aggregate variance.

• Commission applied outside contracted per-SKU-category rate. The platform contract typically specifies commission at differential rates across SKU categories — over-the-counter versus prescription, chronic-care versus acute-care, own-brand versus third-party fulfilment. A settlement report that applies the flat commission rate rather than the SKU-category-specific rate creates a per-order variance that only surfaces in aggregate reconciliation. Reconciliation discipline: the outward-supply register carries the SKU-category tag per order, the settlement report is ingested at ORDER-ID level, and the commission variance per SKU category is a distinct reconciliation line.

• Section 34 credit note issued outside the month of the physical return. An expired-stock return that ships back in month M with the credit note issued in month M+1 creates a straddle where the marketplace’s GSTR-8 for month M does not net the return, the supplier’s GSTR-1 for month M shows the gross output, and the supplier’s Section 34 credit note in month M+1 creates a downstream reconciliation with a one-month lag. Section 34(2) permits declaration up to 30 November of the following FY, so the legal position is clean — but the operating friction is real. Reconciliation discipline: the reverse-logistics tracker triggers a same-month Section 34 credit note issue for every return processed by the marketplace’s bonded warehouse.

• TCS-credit-in-transit not tracked as a working-capital line. The two-month lag between TCS deduction at the weekly settlement point and credit availability in the supplier’s electronic cash ledger via GSTR-2A / GSTR-2B is a real working-capital drag — for a Tier-1 pharma D2C channel running Rs 135 crore quarterly gross across three platforms at Rs 41.8 lakh per-platform per-quarter TCS, the aggregate TCS-credit-in-transit balance sits at approximately Rs 1.25 crore at steady state. A finance team that does not track this as a distinct working-capital line under-reports its true operating cash cycle. Reconciliation discipline: the TCS-credit-in-transit tracker is a first-class treasury line in the monthly close.

• Payment gateway charges on gross rather than net collected. The payment aggregator tariff typically applies at the transaction level (per-purchase) at 1.8 percent of the gross value collected, not on the net-of-returns base. A settlement report that applies the payment gateway charge on the net-of-returns base under-charges the supplier at the settlement point and creates a subsequent adjustment when the payment aggregator reconciles at month-close. Reconciliation discipline: the payment gateway charge line is reconciled at the gross-value level per transaction, not at the aggregate net level.

The full set of pharma D2C reconciliation breakages sits alongside the broader marketplace and settlement failure-mode reference at GSTR-2B ITC reconciliation failure modes and the operating discipline framework at reconciliation playbook for monthly close — both of which anchor the standing-close process that the pharma D2C team runs.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the weekly settlement report from each of the three marketplaces at ORDER-ID granularity, cross-walks each order to the pharma supplier’s own outward-supply register from the ERP, and reconciles at the SKU-category-specific commission rate, the per-order logistics tariff, the transaction-level payment gateway rate, and the Section 52 TCS on the correct net-of-returns base. The platform holds the Section 34 credit-note register for the reverse-logistics leg keyed to a return-reason taxonomy (expired-stock, damaged-shipment, wrong-SKU, prescription-verification-failure) and reconciles each credit note against the marketplace’s subsequent-month GSTR-8 net-of-returns base. The two-month TCS-credit-in-transit tracker runs as a treasury-line ageing report, and the monthly TCS-and-tax reconciliation pack consolidates the aggregate TCS credit across all three platforms into a single line for utilisation in the supplier’s GSTR-3B. Match rate improvement of 51 to 88 percent on the platform-settlement-to-outward-register reconciliation, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling, is what makes the platform an infrastructure investment for a Tier-1 pharma D2C channel running a multi-platform e-pharmacy footprint rather than a spreadsheet substitute for the weekly settlement review.

Cross-cluster bridges and where to read next

The Section 52 TCS reconciliation for the e-pharmacy channel documented in this article sits alongside the parallel Wave D siblings that unpack the other tax-and-regulatory reconciliation surfaces that a pharma company runs. The DPCO 2013 NPPA ceiling price overcharging recovery reconciliation walkthrough covers the parallel domestic-price-control reconciliation for scheduled formulations on the National List of Essential Medicines. The ANDA milestone payment US FDA tentative approval revenue timing walkthrough covers the parallel milestone-payment reconciliation for the US generic export channel. The Section 194Q TDS API raw material purchase pharma reconciliation walkthrough covers the parallel Section 194Q TDS reconciliation on the raw-material inbound side — a companion reconciliation surface for any pharma finance team running both a marketplace outbound channel and a bulk raw-material inbound base.

The methodology framework for building the per-platform per-week reconciliation workbook — mapping every settlement line to a distinct reconciliation surface, holding parallel platform-applied and base-case computations, and building the credit-note discipline into the standing close process — sits in Terra Insight’s own reconciliation failure mode analysis pillar and the human errors detection envelope trust reference. The commercial pillar for the pharma sub-cluster is Pharma reconciliation software India; the broader authority for the platform is reconciliation software India with the specialised GST reconciliation software surface for the Section 52 TCS credit and Section 34 credit-note reconciliation. The pharma cluster hub is the discovery surface for the full pharma article cluster.

The five FAQs below address the operational questions Indian pharma direct-to-consumer channel controllers and marketplace-reconciliation leads ask most often when running a standing weekly settlement close against the three principal Indian e-pharmacy marketplaces.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 17 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024